In a report released today, Michael Petusky from Barrington maintained a Buy rating on BioScrip Inc (BIOS), with a price target of $4.50. The company’s shares opened today at $3.22, close to its 52-week high of $3.36.
Petusky wrote:
“We continue to model further improvement in gross margin over the next couple of years.”
Petusky has an average return of 3.8% when recommending BioScrip Inc.
According to TipRanks.com, Petusky is ranked #398 out of 4907 analysts.
Currently, the analyst consensus on BioScrip Inc is a Moderate Buy with an average price target of $4.50.
See today’s analyst top recommended stocks >>
Based on BioScrip Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $8.17 million. In comparison, last year the company had a GAAP net loss of $12.52 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioScrip, Inc. engages in the provision of home infusion and home care management solutions. It partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services.
